# Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

> **NCT02262650** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT02262650
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2004-05
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262650, "Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02262650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*